The high expression levels of DRAXIN have been observed in small-cell lung carcinoma (SCLC) [37], as well as in glioma tumor tissues and cell lines; DRAXIN has been proposed to function as an oncogene, as its knockdown significantly inhibits the proliferation and invasion of glioma cells [38]. Here, DRAXIN is linked to glioma.